Yan Wang1,2, Kai Chen1,2, Yaping Yang1,2, Luyuan Tan1,2, Lili Chen1,2, Liling Zhu1,2, Fengxi Su1,2, Xue Liu3, Shunrong Li1,2. 1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 2. Department of Breast Surgery, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 3. College of Basic Medicine, Jining Medical University, Jining 272067, China.
Abstract
BACKGROUND: Male breast cancer (MBC) is a rare malignancy. We aimed to analyze the incidence trends, clinicopathological characteristics, and survival outcomes in early MBC comparison with early female breast cancer (FBC). METHODS: We included eligible MBC and FBC patients with stage I-II disease in the Surveillance, Epidemiology, and End Results (SEER) database from 2000-2015. Joinpoint regression was used to evaluate the trends in age-adjusted incidence. A one-to-four propensity score matching (PSM) analysis was performed to reduce bias in a retrospective study. Survival outcomes were evaluated using Kaplan-Meier analyses with the log-rank test and Cox proportional hazards regression analysis. RESULTS: Trends in the age-adjusted incidence rates of early MBC were stable [2000-2015, annual percentage change (APC) =0.50, 95% confidence interval (CI): -0.1 to 1.1, P=0.102]; however, the incidence of early FBC changed significantly over the time period (2000-2015, APC = 0.30, 95% CI: 0.0 to 0.6, P=0.045). In the matched cohort, unmarried status, higher grade, larger tumor size, and advanced lymph node (LN) status were associated with a higher risk of breast cancer death and death of any causes both in early MBC and FBC patients. The hormone receptor (HR) status was as a prognostic factor in FBC patients, but not in MBC. Early MBC had worse breast cancer-specific survival (BCSS) and overall survival (OS) than early FBC in stage I, stage II and HR-positive subgroup of patients. CONCLUSIONS: The biological behavior, clinicopathological features, and clinical outcomes of early MBC are different from that of FBC. Further studies on individualized treatment approaches in MBC are needed. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Male breast cancer (MBC) is a rare malignancy. We aimed to analyze the incidence trends, clinicopathological characteristics, and survival outcomes in early MBC comparison with early female breast cancer (FBC). METHODS: We included eligible MBC and FBC patients with stage I-II disease in the Surveillance, Epidemiology, and End Results (SEER) database from 2000-2015. Joinpoint regression was used to evaluate the trends in age-adjusted incidence. A one-to-four propensity score matching (PSM) analysis was performed to reduce bias in a retrospective study. Survival outcomes were evaluated using Kaplan-Meier analyses with the log-rank test and Cox proportional hazards regression analysis. RESULTS: Trends in the age-adjusted incidence rates of early MBC were stable [2000-2015, annual percentage change (APC) =0.50, 95% confidence interval (CI): -0.1 to 1.1, P=0.102]; however, the incidence of early FBC changed significantly over the time period (2000-2015, APC = 0.30, 95% CI: 0.0 to 0.6, P=0.045). In the matched cohort, unmarried status, higher grade, larger tumor size, and advanced lymph node (LN) status were associated with a higher risk of breast cancer death and death of any causes both in early MBC and FBC patients. The hormone receptor (HR) status was as a prognostic factor in FBC patients, but not in MBC. Early MBC had worse breast cancer-specific survival (BCSS) and overall survival (OS) than early FBC in stage I, stage II and HR-positive subgroup of patients. CONCLUSIONS: The biological behavior, clinicopathological features, and clinical outcomes of early MBC are different from that of FBC. Further studies on individualized treatment approaches in MBC are needed. 2019 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Male breast cancer (MBC); incidence; prognosis; propensity score matching (PSM)
Authors: Sriram Venigalla; Ruben Carmona; David M Guttmann; Varsha Jain; Gary M Freedman; Amy S Clark; Jacob E Shabason Journal: JAMA Oncol Date: 2018-10-11 Impact factor: 31.777
Authors: Denise Riedel Lewis; Huann-Sheng Chen; Myles G Cockburn; Xiao-Cheng Wu; Antoinette M Stroup; Douglas N Midthune; Zhaohui Zou; Martin F Krapcho; Daniel G Miller; Eric J Feuer Journal: Cancer Date: 2018-03-06 Impact factor: 6.860
Authors: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245
Authors: Karla Kerlikowske; Diana L Miglioretti; Diana S M Buist; Rod Walker; Patricia A Carney Journal: J Natl Cancer Inst Date: 2007-08-14 Impact factor: 13.506
Authors: Julian Hanske; Christian P Meyer; Jesse D Sammon; Toni K Choueiri; Mani Menon; Stuart R Lipsitz; Joachim Noldus; Paul L Nguyen; Maxine Sun; Quoc-Dien Trinh Journal: Prev Med Date: 2016-05-20 Impact factor: 4.018